Vaxcyte Inc. Common Stock vs VICI Properties Inc — how do they compare? Vaxcyte Inc. Common Stock trades at $67.27 (market cap $10.51B), while VICI Properties Inc trades at $23.2 (market cap $25.23B). The key difference: VICI Properties Inc is far larger — about 2.4× Vaxcyte Inc. Common Stock's market cap, and VICI Properties Inc pays a 8.03% dividend while Vaxcyte Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vaxcyte Inc. Common Stock for 0 Days and VICI Properties Inc for 44 Days on average.
| PCVX | VICI | |
|---|---|---|
Market Cap | $10.51B | $25.23B |
Volume | 2,644,694 | 10,007,776 |
Sector | Health | Real Estate |
52-Week High | $73.82 | $31.42 |
52-Week Low | $40.32 | $22.53 |
Typical Hold Time | 0 Days | 44 Days |
Enterprise Value | $9.14B | $42.78B |
Dividend Yield | — | 8.03% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VICI Properties trades at $22.91, down 0.52% on the day, with a bearish technical signal despite strong fundamentals including a 67.5% net income margin and 9.84% ROE. The stock shows mixed earnings performance with one beat and two misses in recent quarters, while analyst consensus remains strongly bullish with a $28.90 price target representing 26% upside. Recent corporate actions include a $0.46 dividend payment scheduled for October 2026.
The investment case balances attractive valuation metrics (P/E of 8.88, P/B of 0.86) against technical weakness and tenant concentration risks. While cash flow generation remains robust with $2.51B from operations in 2025, investors face headwinds from rising interest rates and potential tenant stress. The 75% buy rating from analysts suggests significant upside potential if execution remains strong.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →